About this trial
Chronic post-mastectomy pain (CPMP) is a significant issue affecting many women after mastectomy. Factors like age, treatment type, and pre-surgery pain can increase the risk of developing this condition. By evaluating these factors, CPMP can be prevented more successfully and treatment strategies can be developed. This study aims to investigate the factors contributing to CPMP and contribute to the existing literature on this important topic.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Between the ages of 18-80
BMI 18-35 kg/m2
ASA (American Society of Anesthesiologists) Scoring I-II-III
Elective mastectomy surgery
Disqualifiers
Patients under 18 and over 80 years of age
Patients who do not want to participate in the study
Patients with chronic pain or chronic opioid use
Patients with alcohol, substance or drug addiction
Trial population
Patients aged 18-80 years, with an ASA classification of I-II-III and a body mass index (BMI) between 18-35 kg/m², who will undergo mastectomy surgery or mastectomy with axillary dissection, will be included in our study.
Trial design
Cohort
Prospective
Treatments tested in this trial
Breast Cancer Surgery Pain
Procedure/SurgeryFactors affecting the occurrence of chronic pain in patients undergoing elective mastectomy surgery will be investigated.
Treatment groups
Trial outcomes
Primary outcomes
Self-leeds assessment of neuropathic symptoms and sign findings in 3rd months.
Patients; self-Leeds assessment of neuropathic symptoms and sign (S-LANSS) findings will be evaluated in the 3rd postoperative month. Patients with an S-LANSS score of 12 and above will be diagnosed with chronic neuropathic pain. In this scoring, the patient can get at least 0 points. He can get a maximum of 24 points. If the patient's score is 12 or above, the possibility of neuropathic pain is considered high.
Secondary outcomes
Short Form 12 questionnaire in the 3rd month
Short Form 12 questionnaire will be evaluated in the 3rd month to evaluate the quality of life of the patients.
Short Form 12 questionnaire in the 6th month
Short Form 12 questionnaire will be evaluated in the 6th month to evaluate the quality of life of the patients
Self-leeds assessment of neuropathic symptoms and sign findings at 6th months
Patients; self-Leeds assessment of neuropathic symptoms and sign (S-LANSS) findings will be evaluated in the 3rd postoperative month. Patients with an S-LANSS score of 12 and above will be diagnosed with chronic neuropathic pain. In this scoring, the patient can get at least 0 points. He can get a maximum of 24 points. If the patient's score is 12 or above, the possibility of neuropathic pain is considered high.
Acute pain score
Pain will be assessed at rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain). Pain assessment will be made at 0, 1, 24th hours in the postoperative period.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.